证券代码：300146 证券简称：汤臣倍健 汤臣倍健股份有限公司 投资者关系活动记录表 编号：2023-007 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他投资者电话会 详见附件 参与单位名称及 | --- | --- | --- | |----------|--------------------------------------------|----------------------------| | 人员姓名 | 单位名称的完整性和准确性，敬请投资者注意。 | | | | 2023 年 6 月 16 日 | 14:30-15:30 特定对象调研； | | 时间 | | | 2023 年 6 月 20 日 15:15-16:30 投资者电话会 地点 广州市黄埔区科学城科学大道中 99 号科汇金谷三街 3 号公司会议室 上市公司接待人 员姓名 公司董事会秘书唐金银、证券事务代表关艳村 会议采取互动问答形式，主要交流内容如下： Q：2022 年公司境内线下收入同比下滑，VDS 行业是否正增长 欧睿数据显示，2022 年中国维生素与膳 ...

证券代码：300146 证券简称：汤臣倍健 汤臣倍健股份有限公司 投资者关系活动记录表 编号：2023-006 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他投资者电话会 详见附件 参与单位名称及 | --- | --- | --- | --- | |----------|--------------------------------------------|--------------------------|----------------| | 人员姓名 | 单位名称的完整性和准确性，敬请投资者注意。 | | | | | 2023 年 5 月 24 日 | 15:30-16:30、16:40-18:30 | 投资者电话会； | | 时间 | | | | 2023 年 5 月 25 日 16:00-17:30 特定对象调研 地点 广州市黄埔区科学城科学大道中 99 号科汇金谷三街 3 号公司会议室 上市公司接待人 员姓名 公司董事会秘书唐金银、证券事务代表关艳村 会议采取互动问答形式，主要交流内容如下： Q：回顾公司创业历史，公司在 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥3,108,119,772.05, representing a 36.30% increase compared to ¥2,280,271,630.40 in the same period last year[3] - Net profit attributable to shareholders was ¥1,029,519,641.37, a 55.27% increase from ¥663,007,234.38 year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥994,652,011.53, up 46.06% from ¥680,935,725.28 in the previous year[3] - Basic earnings per share increased to ¥0.61, reflecting a 56.41% rise from ¥0.39 in the same quarter last year[4] - Total operating revenue for the period reached ¥1,327,973,775.78, a significant increase from ¥854,502,742.45 in the previous period, representing a growth of approximately 55.4%[23] - Net profit for the period was ¥1,049,914,368.08, compared to ¥664,786,735.95 in the previous period, indicating a year-over-year increase of about 58%[23] - Basic earnings per share rose to ¥0.61, up from ¥0.39 in the previous period, reflecting a growth of 56.4%[24] - Operating profit increased to ¥1,286,246,347.19, compared to ¥821,546,213.44 in the previous period, marking a growth of approximately 56.5%[22] - Total comprehensive income for the period was ¥999,193,999.93, compared to ¥719,630,838.93 in the previous period, representing an increase of about 38.9%[24] Cash Flow and Assets - The company's cash flow from operating activities was ¥665,857,256.12, a significant recovery from a negative cash flow of ¥45,114,075.46 in the same period last year[3] - Cash and cash equivalents increased by CNY 66,108.26 million, a change of 289.46% year-on-year, driven by sales growth, improved collections, and recovery of large deposits and financial products[9] - Cash inflow from investment activities amounted to ¥2,851,649,098.28, significantly higher than ¥573,413,952.59 in the previous period[26] - The net increase in cash and cash equivalents was 661,082,633.87, contrasting with a decrease of -348,932,763.25 in the prior period[27] - The ending balance of cash and cash equivalents reached 3,619,597,391.58, compared to 2,551,326,587.08 previously[27] Liabilities and Equity - The total assets at the end of the reporting period were ¥13,635,474,391.00, a 3.60% increase from ¥13,157,665,481.56 at the end of the previous year[4] - The total liabilities increased to CNY 1.878 billion from CNY 2.406 billion at the beginning of the year[21] - The total equity attributable to shareholders reached CNY 11.674 billion, up from CNY 10.693 billion[21] Revenue Breakdown - Domestic business revenue reached CNY 1.878 billion, with the main brand "汤臣倍健" contributing CNY 1.878 billion, up 45.41% year-on-year[15] - Online channel revenue grew by 90.98% year-on-year, accounting for approximately 66.95% of domestic revenue[15] - The overseas business, LSG, generated revenue of CNY 266 million, a year-on-year increase of 58.33%[15] Tax and Expenses - Income tax expenses for the period were CNY 27,805.94 million, an increase of 46.57% year-on-year, mainly due to increased profits during the reporting period[8] - The company’s tax expenses increased to ¥278,059,407.70 from ¥189,716,006.50, reflecting higher profitability[23] Other Financial Metrics - The return on equity (ROE) rose to 9.21%, an increase of 3.10 percentage points compared to 6.11% in the previous year[4] - Accounts receivable increased by 57.55% to ¥520,458,300.00, primarily due to credit extended to customers at the beginning of the year[7] - Non-recurring gains totaled ¥34,867,629.84, primarily from government subsidies and bank financial product income[5] - Asset impairment losses for the period were CNY -407,500, a decrease of 57.44% year-on-year, mainly due to reduced inventory write-down provisions[8] - Other comprehensive income after tax was CNY -50,720.40 million, a change of 192.48% year-on-year, primarily due to fluctuations in foreign currency translation differences[8] Future Outlook - The company plans to continue expanding its product offerings and market presence, focusing on health-related products[15] Audit Status - The first quarter report was not audited[28]

Financial Performance - In 2022, the company achieved a sales revenue of 7.861 billion RMB, a year-on-year increase of 5.79%, while the net profit attributable to shareholders was 1.386 billion RMB, a year-on-year decrease of 20.99%[3]. - The company's revenue for 2022 was approximately ¥7.86 billion, representing a 5.79% increase compared to ¥7.43 billion in 2021[27]. - Net profit attributable to shareholders for 2022 was approximately ¥1.39 billion, a decrease of 20.99% from ¥1.75 billion in 2021[27]. - The net cash flow from operating activities for 2022 was approximately ¥1.38 billion, down 24.19% from ¥1.82 billion in 2021[27]. - Basic earnings per share for 2022 were ¥0.82, a decline of 22.64% compared to ¥1.06 in 2021[27]. - The company's fourth-quarter revenue was approximately ¥1.70 billion, with a net profit attributable to shareholders of approximately -¥96 million[29]. - The company reported a weighted average return on equity of 13.46% for 2022, down 5.88 percentage points from 19.34% in 2021[27]. Market Position and Opportunities - The retail market size for vitamins and dietary supplements in China was 200.1 billion RMB in 2022, with a growth rate of approximately 4.9%, and the company's market share stood at 10.3%, maintaining the leading position[3]. - The aging population in China presents significant growth opportunities for the dietary supplement market, with projections indicating that by 2050, 24% of the population will be aged 65 and above[7]. - The aging population in China is projected to exceed 300 million by 2025, creating significant market opportunities for the dietary supplement industry[33]. Product Development and Innovation - The company has developed over 30 customized raw materials and obtained 96 invention patents related to raw materials and formulations[36]. - The company is focusing on research in areas such as anti-aging and precision nutrition, establishing a long-term layout for new functional products[48]. - The company has introduced a new probiotic tablet formulation as part of its product expansion strategy[54]. - The company aims to implement a long-term goal of comprehensive health interventions through scientific nutrition, focusing on precision nutrition and health improvement[36]. Quality Control and Management - The company emphasizes quality control as a core value, with a commitment to exceed national standards and maintain strict quality management practices[11]. - The company is enhancing its quality management processes by investing in precision inspection equipment and training quality management personnel[11]. - The company has established a continuous and intelligent production line, enhancing production efficiency and product quality[37]. Strategic Initiatives and Future Plans - The year 2023 is viewed as a pivotal time for new strategic layouts in the post-pandemic era, marking the beginning of a new growth cycle for the company[9]. - The company aims to increase its market share in the saturated basic nutrient market while actively pursuing new product development in untapped markets[5]. - The company plans to achieve a double-digit revenue growth in 2023 compared to the previous year, although this goal is subject to uncertainties in the future operating environment[120]. Risks and Challenges - The company faces risks from rising raw material prices, which could impact product gross margins, and is actively managing supplier relationships to mitigate these risks[13]. - The company acknowledges the increasing regulatory scrutiny in the dietary supplement industry, which may impact long-term development and competitive dynamics[12]. - The company is experiencing intensified competition from international brands entering the Chinese market and is focusing on enhancing its research and development capabilities[14]. Corporate Governance and Compliance - The company emphasizes its commitment to improving corporate governance in accordance with relevant regulations, ensuring compliance and operational independence[133]. - The company maintains a clear separation from its controlling shareholder, ensuring independent operations and decision-making[133]. - The company has established specialized committees within the board to provide professional opinions and support decision-making processes[134]. Investor Relations and Communication - The company held multiple investor communication activities throughout 2022, including online meetings and phone communications with various institutional investors[131]. - The company actively engages with investors to discuss future development prospects and operational strategies[132]. - The company emphasizes investor relations management, utilizing multiple channels for communication, including online performance briefings and investor visits[135]. Social Responsibility and Sustainability - The company has engaged in over 14,000 public welfare activities since 2011, including the "Health Express Nutrition China Tour" initiative[187]. - The company donated over 10 million RMB to support UNICEF's projects on infant nutrition from 2020 to 2022[188]. - The company has committed to sustainable practices in energy conservation and greenhouse gas emissions reduction[186].

汤臣倍健股份有限公司 关于举行 2022 年度网络业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 证券代码：300146 证券简称：汤臣倍健 公告编号：2023-016 汤臣倍健股份有限公司（以下简称"公司"）《2022 年年度报告》于 2023 年 3 月 18 日在巨潮资讯网披露。为便于广大投资者进一步了解公司经营情况及未来发展规划，公 司将于 2023 年 3 月 28 日举行 2022 年度网络业绩说明会，欢迎广大投资者积极参与。 特此公告。 汤臣倍健股份有限公司 董 事 会 二〇二三年三月十七日 1.召开时间：2023 年 3 月 28 日（星期二）15:00-17:00 2.出席人员：公司董事、总经理林志成先生，独立董事邓传远先生，董事会秘书唐 金银女士，财务总监吴卓艺女士。 3.接入方式：投资者可登陆深圳证券交易所"互动易"平台（http://irm.cninfo.com.c n） 进入"云访谈"栏目参与公司 2022 年度网络业绩说明会。 二、征集问题事项 为做好中小投资者保护工作，增进投资者对公司的了解和认同，提升交流针对性 ...